Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $1.7 million.

  • Puma Biotechnology's Share-based Compensation fell 18.55% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 20.68%. This contributed to the annual value of $8.2 million for FY2024, which is 19.54% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Share-based Compensation is $1.7 million, which was up 2.76% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Share-based Compensation registered a high of $18.2 million during Q2 2021, and its lowest value of $1.6 million during Q2 2025.
  • Its 3-year average for Share-based Compensation is $2.2 million, with a median of $2.1 million in 2024.
  • In the last 5 years, Puma Biotechnology's Share-based Compensation surged by 71.58% in 2021 and then crashed by 82.35% in 2022.
  • Puma Biotechnology's Share-based Compensation (Quarterly) stood at $4.3 million in 2021, then slumped by 38.19% to $2.6 million in 2022, then dropped by 7.46% to $2.4 million in 2023, then declined by 27.96% to $1.8 million in 2024, then declined by 18.55% to $1.7 million in 2025.
  • Its Share-based Compensation was $1.7 million in Q3 2025, compared to $1.6 million in Q2 2025 and $2.0 million in Q1 2025.